Tryptamine Therapeutics (ASX:TYP) ROCE % : -230.50% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tryptamine Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2024 was -230.50%.

Tryptamine Therapeutics ROCE % Historical Data

The historical data trend for Tryptamine Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics ROCE % Chart

Tryptamine Therapeutics Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

-38.75

-149.06

-100.10

-69.37

-102.09

Tryptamine Therapeutics Semi-Annual Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Dec24
ROCE %	Get a 7-Day Free Trial								-38.72	-190.36	-15.29	-111.45	-230.50

Tryptamine Therapeutics ROCE % Calculation

Tryptamine Therapeutics's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-6.799	/	( ( (13.614 - 4.461)	+	(5.881 - 1.714) )	/ 2 )
	=	-6.799	/	( (9.153	+	4.167)	/ 2 )
	=	-6.799	/	6.66
	=	-102.09 %

Tryptamine Therapeutics's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Dec. 2023 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Dec. 2023 )		(Q: Dec. 2024 )
	=	-8.042	/	( ( (3.083 - 0.341)	+	(5.295 - 1.059) )	/ 2 )
	=	-8.042	/	( ( 2.742	+	4.236 )	/ 2 )
	=	-8.042	/	3.489
	=	-230.50 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

Tryptamine Therapeutics (ASX:TYP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tryptamine Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tryptamine Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

TYPTF:USA

Address

C/o Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124

Website

https://www.tryptherapeutics.com

Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).

Tryptamine Therapeutics Headlines

No Headlines